Results 31 – 40 of 129 for iressa gefitinib (0.04 seconds)

Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-small cell lung cancer

innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and ...

Update on PEARL Phase III trial of Imfinzi monotherapy in Stage IV non-small cell lung cancer

innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) ...

Renee Bailey Iacona

analysis plans. Served as statistical team lead for the IRESSA Breast Clinical Program and investigator initiated trials, and chair of Biomarker ...

Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn

including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) ...

AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)

(olaparib) in the U.S. and Europe, the approval of IRESSA® (gefitinib) in the US, rapid US and EU filings for AZD9291, key regulatory designations for ...

Imfinzi is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer

patients in Asia, with our approved medicines Iressa (gefitinib) and Tagrisso (osimertinib), and ongoing Phase III trials ADAURA, ...

Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer

patients in Asia, with our approved medicines Iressa (gefitinib) and Tagrisso (osimertinib), and ongoing Phase III trials ADAURA, ...

Imfinzi granted US Orphan Drug Designation for small cell lung cancer

patients in Asia, with our approved medicines Iressa (gefitinib) and Tagrisso (osimertinib) and ongoing Phase III trials FLAURA, ...

Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer

patients in Asia, with our approved medicines Iressa (gefitinib) and Tagrisso (osimertinib), and ongoing Phase III trials ADAURA, ...

Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer

patients in Asia, with our approved medicines Iressa (gefitinib) and Tagrisso (osimertinib), and ongoing Phase III trials ADAURA, ...

Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next